Skip to main content
Clinical Trials/IRCT20100127003200N5
IRCT20100127003200N5
Not yet recruiting
Phase 3

Efficacy and safety of human dermal fibroblasts cultured in clinical-grade large scale cultured system compared to placebo in treatment of nasolabial folds : A randomized, placebo controlled phase 3, parallel, double blinded clinical trial

Barkat pharmaceutical group0 sites60 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Barkat pharmaceutical group
Enrollment
60
Status
Not yet recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Barkat pharmaceutical group

Eligibility Criteria

Inclusion Criteria

  • Age between 30\-60 years
  • Having nasolabial folds
  • Wrinkle Assessment Scale between 3 to 5
  • Nasolabial fold line length between 12\-15 cm
  • Written consent to participate and willingness to attend in regular treatment / follow up visits

Exclusion Criteria

  • Having a known chronic disease
  • pregnancy or plan to be pregnant during the next 5 years
  • history of cancer or chemotherapy
  • Having viral disease: HIV, HBV or HCV
  • History of cell therapy
  • History of lipotransfer at the nasolabial region
  • UV, laser or PRP interventions in the last 6 months
  • History of organ transplantation or blood transfusion
  • History of allergy to anesthetic drugs
  • History of using immunosuppresive or cytotoxic drugs in the last 6 months

Outcomes

Primary Outcomes

Not specified

Similar Trials